[en] Natalizumab (Tysabri((R))) is highly efficacious in controlling disease activity in relapsing multiple sclerosis (MS) patients. As it is one of the more recent therapies for MS, there remains a need for long-term safety and efficacy data of natalizumab in a clinical practice setting. The Tysabri observational program (TOP) is an open-label, multicenter, multinational, prospective observational study, aiming to recruit up to 6,000 patients with relapsing-remitting MS from Europe, Canada and Australia. The objectives of this study are to collect long-term safety and efficacy data on disease activity and disability progression. We report here the interim results of the 563 patients included in TOP between December 2007 and 2012 from Belgium. This patient cohort was older at baseline, had longer disease duration, higher neurological impairment, and a higher baseline annualized relapse rate, when compared to patients included in the pivotal phase III AFFIRM trial. Nevertheless, the efficacy of natalizumab was comparable. The annualized relapse rate on treatment was reduced by 90.70 % (p < 0.0001) with a cumulative probability of relapse of 26.87 % at 24 months. The cumulative probabilities of sustained disability improvement and progression at 24 months were 25.68 and 9.01 %, respectively. There were no new safety concerns over the follow-up period. Two cases of progressive multifocal leukoencephalopathy were diagnosed. Our results are consistent with other observational studies in the post-marketing setting.
Disciplines :
Neurology
Author, co-author :
van Pesch, Vincent
Bartholome, Emmanuel
Bissay, Veronique
Bouquiaux, Olivier
Bureau, Michel
Caekebeke, Jo
Debruyne, Jan
Declercq, Inge
Decoo, Dany
Denayer, Pierre
De Smet, Eric
D'hooghe, Marie
Dubois, Benedicte
Dupuis, Michel
Sankari, Souraya El
Geens, Karine
Guillaume, Daniel ; Université de Liège - ULiège > Département des sciences cliniques > Médecine générale
Polman CH et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9): 899-910.
Rudick RA et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354(9): 911-923.
Sandborn WJ et al (2005) Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353(18): 1912-1925.
Phan-Ba R et al (2012) MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry 83(2): 224-226.
Butzkueven H et al (2014) Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry. doi: 10. 1136/jnnp-2013-306936.
Piehl F et al (2011) Swedish natalizumab (Tysabri) multiple sclerosis surveillance study. Neurol Sci 31(Suppl 3): 289-293.
Oturai AB et al (2009) Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 16(3): 420-423.
Melin A et al (2012) Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis. J Neurol 259(6): 1215-1221.
Outteryck O et al (2010) Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol 257(2): 207-211.
Fernandez O et al (2012) Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study. J Neurol 259(9): 1814-1823.
Sangalli F et al (2010) Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci 31(3): 299-302.
Prosperini L et al (2010) Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome. Neurol Sci 31(3): 303-307.
Putzki N et al (2010) Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol 17(1): 31-37.
Holmen C et al (2011) A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler 17(6): 708-719.
Bloomgren G et al (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366(20): 1870-1880.
Kappos L et al (2012) Long-term safety and efficacy and association between baseline treatment history and postbaseline relapses in multiple sclerosis patients treated with natalizumab in the TYSABRI(R) observational program (TOP) (P04. 134). Neurology 78: P04. 134.
Spelman (2012) Comparison of natalizumab and interferon-beta/glatiramer acetate efficacy using a propensity-matched registry data (S133). Mult Scler J 18(4 suppl): 9-53.
Hutchinson M et al (2009) The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 256(3): 405-415.